• Investors may be wondering if Eli Lilly at around US$1,105 per share is still priced for opportunity or if it already reflects the market's optimism about its future.
• The stock has returned 3.8% over the past week, 29.8% over the last month, 2.3% year to date, and 50.9% over the past year. This naturally raises questions about how much potential or risk is now reflected in the price.
• These moves are occurring against a backdrop of ongoing attention on Eli Lilly's drug portfolio and pipeline, along with sustained interest from investors who follow large pharmaceutical stocks closely. Together, these factors help explain why the current share price is drawing so much focus from investors assessing whether it still fits their expectations.
• Eli Lilly currently has a valuation score of 2 out of 6. Next, you will see how different valuation approaches interpret that score, as well as a broader way to think about value that ties everything together at the end of the article.

Eli Lilly scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Eli Lilly Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model estimates what a stock could be worth by projecting the cash it might generate in the future and then discounting those cash flows back to today.

For Eli Lilly, the 2 Stage Free Cash Flow to Equity model starts with last twelve months free cash flow of about $8.6b. Analysts provide detailed forecasts out to 2030, with projected free cash flow of $46.8b in that year. Beyond the analyst window, Simply Wall St extrapolates additional yearly cash flows, all expressed in $ and discounted back to today.

When all these projected and extrapolated cash flows are added and discounted, the model arrives at an estimated intrinsic value of about $1,404 per share. Compared with the current share price of around $1,105, the DCF output implies Eli Lilly trades at roughly a 21.3% discount, which indicates the stock is undervalued according to this model.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Eli Lilly is undervalued by 21.3%. Track this in your watchlist or portfolio, or discover 46 more high quality undervalued stocks.

Approach 2: Eli Lilly Price vs Earnings

For profitable companies, the P/E ratio is a useful way to think about what you are paying for each dollar of earnings, which is often the main driver of long term returns. Higher expected earnings growth and lower perceived risk usually support a higher, or more generous, P/E ratio, while lower growth and higher risk tend to justify a lower P/E.

Eli Lilly currently trades on a P/E of about 39x. That sits well above the Pharmaceuticals industry average P/E of about 15.4x and also above the peer group average of roughly 23.6x. To add more context, Simply Wall St calculates a proprietary “Fair Ratio” of around 37.7x for Eli Lilly. This Fair Ratio reflects factors such as the company’s earnings profile, industry, profit margins, market capitalization and risk characteristics.

Because the Fair Ratio is tailored to the specific company, it can be more informative than simple comparisons with broad industry averages or a selection of peers, which may have very different growth outlooks, risk levels or profitability. In Eli Lilly’s case, the current P/E of 39x is only slightly above the Fair Ratio of 37.7x, which points to a valuation that is broadly in line with what this framework would suggest.

Result: ABOUT RIGHT

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Eli Lilly Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives take the story you believe about Eli Lilly, link it to a set of revenue, earnings and margin forecasts, turn that into a Fair Value, and then let you compare that Fair Value with the live share price on Simply Wall St’s Community page. Narratives are kept up to date as new earnings or news arrive. This is why one investor on the platform can reasonably view Eli Lilly as worth around US$899 per share while another sees a case for US$1,500 per share, each with a clear, transparent story and set of numbers behind their view.

For Eli Lilly, here are previews of two leading Eli Lilly narratives to make comparison easier:

Each narrative connects a clearly stated story to specific forecasts and a Fair Value, so you can see which version feels closer to how you see the stock today.

Fair Value in this narrative: about US$1,189 per share.

At a last close of US$1,105, this narrative views the stock as trading at roughly a 7.1% discount to its Fair Value.

Revenue growth assumption: 20% a year.

• GLP 1 drugs, especially Mounjaro and Zepbound, sit at the center of the story, supported by analyst sales forecasts, low current market penetration and expectations for ongoing insurance coverage across diabetes and obesity treatments.
• Production capacity is treated as the main constraint, with large manufacturing projects expected to ease bottlenecks over time so volume can catch up with demand.
• The Fair Value of around US$1,200 per share is based on several years of 20% to 25% revenue growth and a 9% discount rate, while noting that competition and pricing beyond the next decade are harder to pin down.

Fair Value in this narrative: about US$900 per share.

At a last close of US$1,105, this narrative views the stock as trading roughly 22.8% above its Fair Value.

Revenue growth assumption: 12.33% a year.

• The focus is on pressure from potential U.S. drug pricing reforms, efforts to narrow price gaps between regions and tighter reimbursement, which together could limit pricing power for obesity and diabetes drugs.
• Heavy reliance on a small group of GLP 1 products, along with the risk of new entrants, generic and biosimilar competition and higher R&D and safety requirements, is treated as a key vulnerability.
• The Fair Value of about US$900 per share reflects a scenario where earnings grow but the P/E contracts to around 24x by 2029 and the stock aligns more with the lower end of analyst price targets.

If you want to see how these and other community views compare with your own expectations, you can use the full set of narratives as a reference point rather than relying on a single headline number.

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Eli Lilly on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Do you think there's more to the story for Eli Lilly? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.